Aernoud Fiolet

367 Clinical implications and future perspectives Table 2. Continued. Principle investigator Acronym; trial registration Study name Patients Population Regimen (Expected) Follow-up Primary end point (Estimated) completion date Kelly P CONVINCE; NCT02898610 Colchicine for Prevention of Vascular Inflammation in Non-cardio Embolic Stroke 2623 Prior ischaemic stroke or transient ischaemic attack Colchicine 0.5 mg once daily vs usual care 5 years Any recurrence of non-fatal ischaemic stroke, non-fatal hospitalisation for unstable angina, myocardial infarction, cardiac arrest or vascular death End of 2021 Jolly S CLEAR SYNERGY; NCT03048825 Colchicine and Spironolactone in Patients with Myocardial Infarction / SYNERGY Stent Registry 7000 Acute myocardial infarction with percutaneous coronary revascularisation Colchicine 0.5 mg once daily vs spironolactone 25 mg once daily vs colchicine 0.5 mg and spironolactone 25 mg vs placebo 3 years Composite of death, recurrent target vessel myocardial infarction, stroke or ischaemia-driven target vessel revascularisation 2025 Patel S COLCARDIO-ACS; ACTRN12616000400460 Colchicine Cardiovascular Outcomes in Acute Coronary Syndrome 3000 Acute coronary syndrome in previous 30-45 days and high- sensitivity C-reactive protein ≥2 mg/l Colchicine 0.5 mg once daily vs placebo 3 years Composite of cardiovascular death, acute coronary syndrome, urgent revascularisation or non-fatal stroke 2025 Short term use Conen D COP-AF; NCT03310125 Colchicine For The Prevention Of Perioperative Atrial Fibrillation In Patients Undergoing Thoracic Surgery 2800 Thoracic surgery ≥55 years of age and in sinus rhythm Colchicine 0.5mg tablet twice daily vs placebo for 10 days 14 days Clinically important atrial fibrillation End 2022 Mewton N COVERT-MI; NCT03156816 Colchicine for Left Ventricular Remodeling Treatment in Acute Myocardial Infarction 198 Acute myocardial infarction with primary coronary intervention Colchicine 2 mg loading dose, 0.5mg once daily vs placebo for 5 days 5 days Infarct size (in % of left ventricular mass) as estimated by cardiac magnetic resonance imaging Begin 2022